Evidence map›Paper›PMID 38045410›Full record

ArticlebioRxiv : the preprint server for biology2023

Host-derived oxidized phospholipids initiate effector-triggered immunity fostering lethality upon microbial encounter.

Marco Di Gioia, Valentina Poli, Piao J Tan, Roberto Spreafico, Anne Chu, Alex G Cuenca, Philip Lsm Gordts, Laura Pandolfi, Federica Meloni, Joseph L Witztum and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Marco Di GioiaHarvard Medical School and Boston Children's Hospital, Division of Immunology and Division of Gastroenterology, MA 02115, USA.
Valentina PoliHarvard Medical School and Boston Children's Hospital, Division of Immunology and Division of Gastroenterology, MA 02115, USA.
Piao J TanDepartment of Chemical and Paper Engineering, Western Michigan University, Kalamazoo, MI, USA.
Roberto SpreaficoInstitute for Quantitative and Computational Biosciences, University of California, Los Angeles, Los Angeles, CA, USA.
Anne ChuHarvard Medical School and Boston Children's Hospital, Division of Immunology and Division of Gastroenterology, MA 02115, USA.
Alex G CuencaDepartment of Surgery, Boston Children's Hospital, Boston, MA 02115, USA; Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, MA 02114, USA.
Philip Lsm GordtsDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0001-8282-7658
Laura PandolfiRespiratory Disease Unit IRCCS San Matteo Hospital Foundation, and Department of Internal Medicine and Pharmacology, University of Pavia, Pavia, 27100, Italy Pavia, 27100, Italy.
Federica MeloniRespiratory Disease Unit IRCCS San Matteo Hospital Foundation, and Department of Internal Medicine and Pharmacology, University of Pavia, Pavia, 27100, Italy Pavia, 27100, Italy.
Joseph L WitztumDivision of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Janet ChouHarvard Medical School and Boston Children's Hospital, Division of Immunology and Division of Gastroenterology, MA 02115, USA.
James R SpringsteadDepartment of Chemical and Paper Engineering, Western Michigan University, Kalamazoo, MI, USA.
Ivan ZanoniHarvard Medical School and Boston Children's Hospital, Division of Immunology and Division of Gastroenterology, MA 02115, USA.

Funding

Tissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WITZTUM, JOSEPH L. · 2020 to 2024
$12.2M
Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly75N93019C00044 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2019 to 2023
$11.0M
Type III interferon Control of Mucosal ImmunityR01DK115217 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Scott B Snapper, Ivan Zanoni · 2017 to 2026
$5.6M
Innate control of the inflammatory process during fungal infectionsR01AI121066 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI ZANONI, IVAN · 2016 to 2025
$4.8M
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannansR01AI165505 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Ivan Zanoni · 2021 to 2026
$4.6M
Macrophage immunometabolism controls septic shockR01AI170632 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Ivan Zanoni · 2023 to 2026
$2.5M
NHLBI NIH HHS P01 HL147835NIAID NIH HHS 75N93019C00044NIAID NIH HHS R01 AI121066NIAID NIH HHS R01 AI165505NIAID NIH HHS R01 AI170632NIDDK NIH HHS R01 DK115217
6 · The paper itself

Abstract

Macrophages detect invading microorganisms via pattern recognition receptors that recognize pathogen-associated molecular patterns, or via sensing the activity of virulence factors that initiates effector-triggered immunity (ETI). Tissue damage that follows pathogen encounter leads to the release of host-derived factors that participate to inflammation. How these

Identifiers

PMID38045410
PMCPMC10690175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.